Introduction
Insufficient circulation of oxygenated blood leads to tissue ischemia, often resulting in necrosis and the loss of tissue function. Clinically important settings include chronic ischemia of the heart and limbs, and acute ischemia, such as is observed in the skin following reconstructive plastic surgery. Endogenous angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2), are naturally produced in response to tissue hypoxia and during wound healing. [1] [2] [3] This restorative process is, however, often insufficient to prevent tissue ischemia and necrosis, due in part to the slow kinetics and inadequate secretion of growth factors. Exogenous delivery of either VEGF or FGF-2 by single bolus injection has proven to be efficacious in stimulating localized angiogenesis and improving blood circulation in animal models of myocar-the distal, ischemic region of the flap. Control flaps showed 50% necrosis at 1 week. Capsules releasing either form of VEGF had no effect on flap survival, but induced a modest increase in distal vascular supply. Delivery of FGF-2 significantly improved flap survival, reducing necrosis to 34.2% (P Ͻ 0.001). Flap vascularization was significantly increased by FGF-2 (P Ͻ 0.01), with numerous vessels, many of which had a large lumen diameter, growing in the proximity of the implanted capsules. These results demonstrate that FGF-2, delivered from encapsulated cells, is more efficacious than either VEGF 121 or VEGF 165 in treating acute skin ischemia and improving skin flap survival. Furthermore, these data attest to the applicability of cell encapsulation for the delivery of angiogenic factors for the treatment and prevention of tissue ischemia. Gene Therapy (2001) 8, 523-533. dial and limb ischemia. [4] [5] [6] [7] [8] In light of these results, clinicians have begun evaluating the therapeutic potential of various angiogenic factors in patients. 9 The recent failure of a clinical trial targeting the ischemic heart, where recombinant VEGF 165 protein was administered by a combination of intercoronary and intravenous injections, 10 has highlighted the need for alternative methods of delivering angiogenic factors in a chronic and sitespecific manner.
Gene transfer approaches of administering angiogenic factors offer an attractive alternative to conventional techniques of injecting recombinant proteins. Long-term expression of therapeutic transgenes is possible by direct gene transfer in vivo either through infection by viruses, including adenoviral 11 and adeno-associated vectors 12, 13 or by direct injection of plasmid DNA. 14 Adenoviruses have been employed to continually deliver the angiogenic factors VEGF 165 , 15 FGF-2 (basic FGF), 16 FGF-1 (acidic FGF) 17 and FGF-5 18 in vivo, with each of these molecules stimulating the outgrowth of new vessels at the site of administration. Direct intramuscular injections of 'naked' DNA coding for VEGF 165 can promote development of collateral vessels and improve blood perfusion in pre-clinical and clinical studies of limb ischemia. 19, 20 Gene Therapy
Ex vivo gene therapy strategies may also prove useful for delivering angiogenic factors. Cells engineered to secrete one or several angiogenic proteins could be introduced at the site of ischemia to stimulate new vessel growth. Myoblasts 21, 22 and fibroblasts 23 have been employed in the past to systemically deliver proteins such as erythropoietin and human growth hormone by direct cell transplantation. Ideally, for an angiogenesisbased therapy, it would be desirable to halt treatment after ischemic tissue is revascularized, as prolonged exposure to angiogenic factors could be deleterious. Encapsulating genetically modified cells within a microporous polymer membrane isolates the transplanted tissue from the host and allows the eventual retrieval of engineered cells. Immunoisolating cells in this manner also offers protection of allogeneic and xenogeneic cell lines from cell contact-mediated rejection by the host's immune system. 24 From a safety perspective, this has the advantage that cells can be selected for protein expression and screened for pathogens before use. Additionally, in the unlikely event of capsule rupture, allogeneic and xenogeneic cells would be naturally eliminated by the host's immune system. This technique has permitted the systemic delivery of erythropoietin to animals in both a continuous and regulated fashion. [25] [26] [27] Cell encapsulation has also been employed to locally administer neurotrophic factors (CNTF and GDNF) locally in the central nervous system, both in pre-clinical and clinical studies, for the treatment of neurodegenerative disorders. [28] [29] [30] During reconstructive surgery, skin flaps are employed to cover wounds with poorly vascularized recipient beds where the damage is too extensive to permit repair using a skin graft. A skin flap is comprised of skin and subcutaneous tissue that is transferred from one area of the body to another, while maintaining an attachment to the body (vascular pedicle) for nourishment. A large percentage of flaps employed in the clinic are classified as random pattern skin flaps. These flaps do not contain any direct cutaneous arteries but rather receive their blood supply through a network of small vessels known as the cutaneous dermal-subdermal plexus. Initially, flap survival relies on blood flow via these vessels in the vascular pedicle. As early as 2 days post-operatively, new vascular channels develop within the flap, and connect with vessels in the recipient bed. 20, 31 Despite this burst of angiogenesis, insufficient perfusion pressure and vascular supply to the dermis can prevent complete healing following a skin flap procedure, causing distal flap necrosis to occur.
In this report, cell encapsulation technology was applied for the continuous, localized delivery of angiogenic factors for the treatment of ischemic skin flaps. For this purpose, the murine C 2 C 12 myoblast cell line was engineered to secrete either human VEGF 121 , VEGF 165 or human FGF-2. C 2 C 12 myoblasts were chosen as they are able to produce high levels of recombinant proteins for prolonged periods 25 and they can be induced to differentiate to varying degrees into a post-mitotic state. 32 A rat model of random pattern skin flap necrosis, 33, 34 resembling situations observed in the clinic, was employed to test VEGF and FGF-2 delivered by encapsulated genetically engineered myoblasts. The encapsulated cell implants were evaluated for their ability to improve the overall survival of the distal zone of the ischemic flap and to induce the growth of new blood vessels.
Results
Engineering C 2 C 12 myoblasts to secrete VEGF and FGF-2 The C 2 C 12 myoblast cell line was genetically modified to secrete either human vascular endothelial growth factor (121 or 165 amino acid isoforms -VEGF 121 or VEGF 165 ) or human FGF-2 (basic FGF). Expression of these angiogenic factors was driven by the murine phosphoglycerate kinase (PGK) promoter. This house keeping promoter was previously shown constitutively to drive high levels of erythropoietin expression from stably transfected C 2 C 12 myoblasts, proving to be superior to the CMV and the metallothionein-1 (MT1) promoters. 25 The PGK promoter has also been shown to up-regulate the expression of transgenes under its control in response to hypoxia. 26 Control cells employed during the study were either unmodified C 2 C 12 myoblasts or C 2 C 12 myoblasts transfected with the empty expression vector pPI-Neo-DHFR ( Figure 1a) . To obtain secretion of VEGF, C 2 C 12 myoblasts were transfected with either pPI-VEGF 121 -Neo-DHFR or pPI-VEGF 165 -Neo-DHFR constructs (Figure 1b, c) . Following selection and gene copy amplification with methotrexate, the C 2 C 12 -hVEGF 165 and C 2 C 12 -hVEGF 121 cell lines secreted approximately 1.3 g VEGF/10
6 cells per day and 1.1 g VEGF/10
6 cells per day, respectively. Two C 2 C 12 cell lines producing FGF-2 were generated by transfection with either pPI-FGF-2-Neo-DHFR or pPIIgSP/FGF-2-Neo-DHFR plasmids (Figure 1d , e). pPI-FGF-2-Neo-DHFR contained 5Ј regions upstream of the ATG-start codon for FGF-2 which included several CTGs used as translation initiation codons for longer isoforms of FGF-2. 35 In the pPI-IgSP/FGF-2-Neo-DHFR construct, these 5Ј regions were removed and replaced by the immunoglobulin signal peptide fused to the cDNA of the 18 kDa form of FGF-2, to facilitate secretion of FGF-2 from the cells. Stable C 2 C 12 -FGF-2 and C 2 C 12 -IgSP/FGF- 36 upon which they grow to form a confluent monolayer and do not invade the underlying matrix (Figure 2A, C) . Treatment with an angiogenic factor such as FGF-2 37 or VEGF, 38 directly activates the endothelial cells and induces them to invade the underlying gel, forming branching and anastomosing cell cords (Figure 2B , E, G). Tube-like structures resembling capillaries can be observed beneath the surface monolayer. Invasion was quantified by measuring the total additive length of all cells penetrating into the underlying gel to form cell cords. 38 The kinetics of FGF-2-induced invasion are more rapid and transient when compared with VEGF ( Figure 2I ). Figure 2D shows the behavior of bovine microvascular endothelial (BME) cells cocultured with mock-transfected C 2 C 12 cells. Some spontaneous invasion was observed, but did not differ from that seen with untransfected C 2 C 12 cells (data not shown). When BME cells were cocultured with C 2 C 12 -hVEGF 121 or C 2 C 12 -hVEGF 165 cells, invasion occurred to a degree comparable with than seen with exogenously added rhVEGF 165 ( Figure 2G , H, I) (P Ͻ 0.001 compared with mock-transfected cells at 2 and 4 days). Coculture with FGF-2-transfected C 2 C 12 cells induced invasion which was significant at 2 days (P Ͻ 0.001) and 4 days (P Ͻ 0.005) ( Figure 2F , I), with kinetics that paralleled those observed with exogenously added FGF-2 ( Figure 2E, I ). In cocultures using FGF-2-SP-transfected C 2 C 12 cells, invasion was slightly greater than that seen with mock-transfected cells, but did not reach statistical significance.
Skin flap survival A skin flap model was developed in Wistar rats based on the previous studies of McFarlane et al 33 and Khouri et al 34 ( Figure 3a ). Following post-operative day 1, various degrees of epidermolysis began to appear. By 48 h, fullthickness necrosis became apparent in the distal portion of the flap, with an adjacent zone of hyperemia. At 7 days, flap necrosis was 50.0 ± 3.8%.
To deliver VEGF and FGF-2, the established C 2 C 12 cell lines were encapsulated in titanium-reinforced, 2-cm long, hollow, microporous polymer fibers. The average dose administered to each animal is displayed in Table  1 . VEGF isoforms were released at microgram per day levels from capsules while FGF-2 was secreted at nanogram per day quantities. As both C 2 C 12 -FGF-2 and C 2 C 12 -IgSP/FGF-2 cells secreted comparable levels of FGF-2, data from animals receiving either cell type were pooled for analysis of capsule secretion, flap survival, and angiogenesis. No significant difference was observed between animals treated with either C 2 C 12 -FGF-2 and C 2 C 12 -IgSP/FGF-2 containing capsules (data not shown).
Three, 2-cm long capsules continuously secreting either VEGF 121 , VEGF 165 , or FGF-2 were evenly positioned underneath the distal ischemic zone of the flap at the time of surgery (Figure 3b ). One week later, flap necrosis was Gene Therapy
Figure 2 Coculture of BME and C 2 C 12 cells. (A) Schematic representation of a confluent monolayer of BME cells on a cell-free three-dimensional collagen gel. (B) Schematic representation of C 2 C 12 cells seeded in suspension a three-dimensional collagen gel, overlaid with a second, cell-free gel, containing a monolayer of BME cells on its upper surface. Phase contrast views after 4 days of (C) control BME cells; (D) BME cells cocultured with mock-transfecetd C 2 C 12 cells; (E) rhFGF-2 (10 ng/ml)-treated BME cells; (F) BME cells co-cultured with FGF-2-transfected C 2 C 12 cells; (G) rhVEGF165-treated BME cells; (H) BME cells cocultured with VEGF121-transfected C 2 C 12 cells. Original magnification in C-H = ×50. (I) Quantification of BME cell invasion. The number of photographic fields analyzed for each condition (n) were as follows: for recombinant cytokines:
Control, n = 9; F (FGF-2), n = 9; V165 (VEGF 165 evaluated and microangiography was performed. Control animal groups receiving capsules containing either untransfected C 2 C 12 myoblasts or C 2 C 12 myoblasts expressing the empty vector, showed 55.1 ± 7.8% and 46.8 ± 5.8% necrosis, respectively (Table 2, Figure 4a ). Animals receiving VEGF 121 (52.8 ± 11.3%) or VEGF 165 (53.1 ± 9.7%) had no significant improvement in flap survival over controls (Table 2, Figure 4a ). On the other hand, capsules secreting FGF-2 alone induced a statistically significant Gene Therapy reduction in flap necrosis (P Ͻ 0.001) (Figure 4a ). Animals had a mean necrosis of 34.2 ± 6.3%, with values ranging from 23% to 47% (Table 2) . Photographs representative of animals implanted either with control or FGF-2 secreting capsules are shown in Figure 4b and c, respectively. At 7 days, capsules were explanted from several of the animals receiving VEGF 121 , VEGF 165 , and FGF-2. Cap- Skin flap necrosis is displayed as a percentage of total skin flap area. ***P Ͻ 0.001 versus C 2 C 12 + vector.
Figure 3 Rat model of random pattern skin flap acute necrosis. (a) A 9 cm long by 3 cm wide dorsal skin/panniculus carnosus flap was raised and the sacral axial vessels were cut. The skin flap was designed to have: (I) a survival zone; (II) an intermediate zone; and (III) a necrotic zone. (b) Dorsal skin flap as performed in the rat. For treatment three capsules were positioned at equal distances subcutaneously in the distal region of the skin flap (arrows).
sules releasing FGF-2 secreted slightly higher levels at explant than implant, while devices secreting VEGF 121 and VEGF 165 isoforms produced less protein at explantation versus at implantion (Table 1 ). This may be due to cell growth and/or trophic effects of FGF-2 on myoblasts within the capsules. Histology of FGF-2 capsules at explant showed viable cells in the interior ( Figure 5 ), with very little central necrosis. VEGF releasing capsules typically displayed central necrosis (not shown).
Microangiography
The angiogenic effect of VEGF and FGF-2 on vascular supply within and adjacent to the skin flap was assessed using arteriography. Groups receiving control (empty vector), VEGF 165 and FGF-2 capsules were compared. Owing to the similarities in secretion level and bioactivity of the two VEGF isoforms by the C 2 C 12 cell lines, animals receiving VEGF 121 releasing capsules were not analyzed by microangiography. An angiograph of dorsal skin in unoperated rats reveals the highly organized vessel architecture naturally present in the skin prior to the flap procedure ( Figure  6A ). Microangiography permitted visualization of the change in vascularization within the skin flap, including adjacent tissues under the flap and neighboring unaffected regions of skin ( Figure 6B , C, D). Marked variations in the density of small tortuous vessels were observed in zone I (the proximal, survival zone), with the greatest increase in the FGF-2 group ( Figure 6B, C, D) . In the distal, necrotic zone III of skin flaps, the degree of vascularization varied, depending on the treatment group. Very few vessels were seen in the necrotic zone of control animals ( Figure 6B ). In animals receiving VEGF 165 , a moderate, but not statistically significant improvement of flap vascularization was evident in the distal region ( Figure 6C ). On the other hand, animals administered FGF-2 showed a marked increase in the number of distal blood vessels ( Figure 6D ). In some incidences, vessels were dilated and appeared to target capsules. Quantitative analysis of arteriographs revealed that animals receiving FGF-2 had a significant increase (P Ͻ 0.01) in the number of distally located vessels as compared to controls ( Figure 6E ). In animals administered FGF-2, distal flap vascularization was variable. This can be attributed to differences in the natural process of angiogenesis and to technical variations in vascular tree filling.
Angiogenesis induced by FGF-2 in vivo
The tissue reaction and formation of new vessels in response to the implanted capsules was qualitatively examined at 7 days following the surgical procedure. Lectin immunostaining of the skin flap and the underlying subcutaneous tissues permitted the identification of endothelial cells lining blood vessels. To permit tissue processing, 1-cm capsules were employed that did not contain a reinforcing titanium coil.
A mild tissue reaction was present around control capsules ( Figure 7A ), with few small diameter vessels near to devices ( Figure 7D, G) . Capsules secreting VEGF 165 appeared to induce a stronger tissue response than control capsules ( Figure 7B ); a few small diameter vessels were present after the 7 day implantation period ( Figure  7E , H). Skin flap samples taken from FGF-2-treated animals showed an important tissue response, which was approximately two-to three-fold thicker than observed around VEGF releasing devices ( Figure 7C) . A two-fold lower magnification was required to visualize the entire reaction ( Figure 7C ) as compared with control ( Figure  7A ) and VEGF 165 ( Figure 7B ) implants. Tissue surrounding the capsules measured as thick as 1 mm in places. High magnification revealed the presence of numerous large diameter blood vessels within this tissue in close proximity to the capsule membrane ( Figure 7F, I ).
Discussion
The aim of this study was to explore the potential of encapsulated cells as a means of administering the angiogenic factors VEGF and FGF-2 in a chronic and site-specific manner. Efficacy of this mode of delivery was evaluated employing a model of acute skin flap ischemia. Unlike models of chronic ischemia, tissue necrosis in the distal region of skin flaps begins as early as 24 h following the surgical procedure, progressing rapidly and stabilizing by day 3. These distinct endpoints can be followed both visually and by tactile examination, facilitating evaluation. The rapid onset of skin flap necrosis makes it a challenging model for angiogenesis-based treatments in comparison to chronic models of ischemia where tissue becomes hypoxic, with delayed necrosis.
Encapsulated cells were employed to deliver VEGF and FGF-2 to ischemic skin flaps as this technique is particularly well suited for treatments requiring the continuous delivery of recombinant proteins over the short and long term.
25 C 2 C 12 myoblasts could be engineered to secrete microgram levels of both VEGF 121 and VEGF 165 and nanogram levels of FGF-2. The inclusion of a signal peptide did not increase the level of FGF-2 secretion. Other groups have reported similar levels of FGF-2 
Figure 7 Histology at day 7 after implantation showing the ischemic region of the skin flap including the implanted capsules. Animals received capsules containing either (A), (D), (G) unmodified C 2 C 12 cells; (B), (E), (H) C 2 C 12 VEGF 165 secreting cells; or (C), (F), (I) C 2 C 12 FGF-2 secreting cells. Viable cells were observed inside the capsules of all groups, with some necrosis in the center of capsules containing unmodified and VEGF 165 secreting cells. (F) High magnification reveals the presence of large diameter blood vessels in close proximity to capsules releasing FGF-2 (arrows), while (D) control and (E) VEGF 165 -treated animals show few smaller diameter vessels nearby the capsule membrane. (G), (H), (I) Lectin immunostaining clearly labels these vessels. (A), (B), (C): scale bar = 200 m; (D), (E), (F): scale bar = 100 m; (G), (H), (I): scale bar = 40 m. (Note that the magnification of C is half that of A and B in order to permit visualization of the entire pericapsular tissue reaction, including viable skin.)
secretion by cells engineered by viral vectors. 16, 40 Primary cells modified by a retrovirus to produce FGF-2 using a signal peptide 40 and cell lines transduced with an adenovirus to secrete FGF-2 without a signal peptide 16 have both yielded secretion levels comparable with those observed in this study. Natural release of FGF-2 from cells in the absence of a signal peptide has been shown to occur using a unique export pathway which is independent of the ER/Golgi system. 41 In vitro bioactivity of VEGF and FGF-2 produced by C 2 C 12 cells was assessed in cocultures with BME cells in a three-dimensional collagen gel system. This system assays directly for cytokine-induced angiogenic activity, since the target cells are quiescent endothelial cells, which, in the absence of an angiogenic stimulus, do not invade the collagen gel or form tube-like structures. Mock-transfected C 2 C 12 myoblasts displayed minimal angiogenic activity, probably due to endogenous VEGF produced by these cells following differentiation.
42 C 2 C 12 -VEGF 165 , C 2 C 12 -VEGF 121 and C 2 C 12 -FGF-2 myoblasts induced an invasive response significantly greater than the basal levels of observed with mock-transfected myoblasts. Extent of invasion was less, however, than that observed in response to exogenously added cytokines. Finally, addition of a signal peptide to FGF-2 did not increase its invasion-inducing activity, possibly due to the high affinity of FGF-2 (with or without signal peptide) for the extracellular matrix.
While administering microgram per day levels of VEGF via encapsulated cells had no effect on the survival of skin flaps, a modest increase in the number of distally located small diameter blood vessels was observed near to implants. Few of these vessels were detected by angiography, which is likely to be due to their small size. Treatment of skin flaps with nanogram per day levels of FGF-2 released by capsules significantly reduced flap necrosis over that seen in control groups. A pronounced and significant increase in blood vessel density was also evident in FGF-2-treated animals at the distal region of the flap. In several cases, animals administered FGF-2 also showed a greater number of vessels in the proximal region, with an increase in diameter when compared with controls. These are likely to be newly developed collateral vessels which are required to sustain the increase in blood supply to the distal part of the flap.
The protective effect of FGF-2 in models of acute ischemia has been well documented. Employing a similar skin flap model, several groups have reported results comparable to this study by injecting recombinant FGF-2 either into or under the flap at the time of surgery. 34, [43] [44] [45] Each of these cases employed high single doses of FGF-2, ranging from 1 to 20 g, in comparison to the daily regimens of 2.6 ng employed in this study. The success of FGF-2 in models of acute ischemia is likely to be due to its multipotency, which enables it to induce the proliferation of a variety of cell types, including fibroblasts, endothelial cells and smooth muscle cells. 46 While it is not understood how FGF-2 protects ischemic tissue, it is likely that stimulation of granulation tissue formation, and in particular trophic support for existing vasculature, play an essential role in this process. FGF-2 is also a well known survival factor and mitogen for a number of cell types including endothelial cells. 47 In addition, FGF-2 has been shown to play an important role in controlling vascular tone, which is essential in blood pressure regulation. 48 The role of new vessel growth in this model of acute ischemia is not clear, and is likely to be less important than the aforementioned mechanisms.
The failure of VEGF in this model may be due to its specificity for endothelial cells and the time course of its action. Some small diameter vessel formation was evident in the proximity of VEGF secreting capsules, as observed using lectin immunostaining, suggesting that angiogenesis did occur, but that it was too late and/or was quantitatively insufficient. This is supported by numerous studies employing VEGF administered either as a recombinant protein or as plasmid DNA, in which a significant induction of angiogenesis is observed only 20 to 30 days following treatment. 20, [49] [50] [51] There is also the possibility that the doses of VEGF administered were too low. Appropriate therapeutic dosing of VEGF has become an issue of some concern. 52 The site of VEGF delivery may not have been optimal, since a separate study revealed that intravascular delivery of naked DNA encoding VEGF improved the survival of skin flaps containing vessels arising from a single artery. 53 It is worth noting that in the clinic it is seldom that flaps are vascularized in this manner.
While the present study demonstrates that continuous delivery of nanogram levels of FGF-2 can significantly improve survival of acutely ischemic tissue, this technique may also be suited for treating cases of chronic ischemia. We have also observed that multiple growth factors can be delivered at controlled doses by encapsulating a mixture of engineered cell lines (unpublished data). Potentially, a combination of VEGF and angiopoietin-1 54 could be administered so as to initiate angiogenesis as well as induce the maturation of the newly formed vessels. Treatment with encapsulated cells may have benefits over direct injection of naked DNA, which has the inconveniences of low transfection efficiency and delayed gene expression, not to mention the difficulties associated with interrupting the gene therapy should problems arise. Certainly, continuous administration of unstable molecules such as FGF-2, which has a serum half-life of 2.9 min when injected intravenously, 55 is preferred over single bolus injections. Lower doses can be employed in a site-specific manner, eliminating unwanted side-effects associated with systemic administration.
Cell encapsulation technology is now being tested in clinical trials outside the central nervous system. As our clinical experience increases and becomes further refined, it will be possible to deliver a wide range of therapeutic molecules in the periphery. This may lead to the development of therapies that use encapsulated cells to deliver locally angiogenic factors to ischemic tissue.
Materials and methods
Cloning of human VEGF 121 and VEGF 165 cDNAs using rtPCR The cDNAs for the human VEGF isoforms 121 and 165 were cloned from human peripheral lymphocytes using reverse transcriptase polymerase chain reaction (RT-PCR). Peripheral blood lymphocytes (PBL) were obtained from human peripheral blood by centrifugation on a Ficoll gradient (Pharmacia, Uppsala, Sweden). The PBL were subsequently cultured in AIM-V media (Pharmacia) containing 5 g/ml concanavalin A and 20 ng/ml of human IL-2 for 24 h. The cells were then grown for 6 days in AIM-V media containing 20 ng/ml of human IL-2. At this point the cells were stimulated with 10 ng/ml phorbol myristic acetate and 500 ng/ml ionomycin for 8 h. Total RNA from activated PBL was extracted using Trizol reagent (Life Technologies, Paisley, UK) and single-stranded cDNA was synthesized using a poly dT oligonucleotide as the primer. Annealing of the oligo dT (15 bp) primer with poly-A RNA was performed at 70°C for 5 min followed by cooling on ice for 5 min. The reverse transcription reaction contained DTT (8 mm), 5 × RT buffer, dNTPs (1 mm), RNAse inhibitor (1 U/l) and reverse transcriptase (20 U/l). The human VEGF 121 and 165 cDNAs were amplified by PCR using the VEGF forward: 5Ј-GCGAATTCGGGCCTCCGAAACCATGA-AC-3Ј and the VEGF reverse: 5Ј-GCGAATTCGCTCA-CCGCCTCGGCTTGTG-3Ј primers, both of which contain an EcoRI site for cloning purposes. The reaction mixture contained 0.5 pm of both VEGF forward and reverse primers and 0.5 l of Taq gold polymerase (Perkin Elmer, Wellesley, MA, USA). PCR was carried out for 1 min at 94°C, 2 min at 65°C, and 2 min at 72°C for 35 cycles. The PCR product was subsequently cloned into the pCR2.1 vector (Invitrogen, Carlsbad, CA, USA) to create the pCR2.1-hVEGF 121 and pCR2.1-hVEGF 165 plasmids. All constructs were verified by sequencing.
Expression vector design
The previously described empty expression vector pPINeo-DHFR 25 served as the base plasmid into which the human VEGF 121 , human VEGF 165 and human basic FGF cDNAs were cloned. Briefly, this vector contains the murine phosphoglycerate kinase (PGK) promoter to drive the expression of the transgene, a neomycin resistance gene (Neo) for selection, and a mutated dihydrofolate reductase gene (DHFR), for amplification of gene copy number. The human VEGF 121 and VEGF 165 cDNAs were excised from the pCR2.1-hVEGF 121 and pCR2.1-hVEGF 165 plasmids by EcoRI digestion, and were subcloned into the EcoRI site of the empty pPI-Neo-DHFR vector, creating the pPI-hVEGF 121 -Neo-DHFR and pPIhVEGF 165 -Neo-DHFR constructs.
The human FGF-2 cDNA containing the region extending from base pairs 106 to 1039 (GenBank Accession No. J04513) was a gift from Dr Marco Presta (University of Brescia, Italy). Digestion with EcoRI gave an EcoRI-EcoRI fragment which contained the human FGF-2 cDNA. This region was subcloned into the EcoRI site of the pPI-Neo-DHFR plasmid to create the pPI-FGF-2-Neo-DHFR expression vector. In a second construct, a 19 amino acid sequence coding for an immunoglobulin signal peptide (IgSP) was fused in frame to the FGF-2 cDNA to facilitate its secretion from transfected cells. The full-length IgSP, containing an intron, was amplified from the plasmid pNUT-hCNTF 29 using the IgSP forward primer:
5Ј-CCGCTCGAGCACCATGAAATGCAGC-3Ј and the IgSP reverse primer: 5Ј-GGCCGAATTCACC-CCTGTAGAAAG-3Ј. The forward primer contained the XhoI site and the reverse primer contained the EcoRI site to permit fusion of the IgSp to FGF-2. The amplified fragment was subcloned into the pCR2.1 vector to form pCR2.1-IgSP. The IgSP sequence was excised by digestion with XhoI and EcoRI and subsequently ligated into the reciprocal XhoI-EcoRI sites in the pPI-Neo-DHFR expression vector to form the pPI-IgSP-Neo-DHFR construct.
The FGF-2 cDNA coding for the 18 kDa form of the protein was amplified from the full-length FGF-2 cDNA, using the forward primer: 5Ј-GGGGTGAATTC-GGCAGCCGGGAGCATCACC-3Ј and the reverse primer: 5Ј-GGATTGCGGCCGCCCTCAGCTCTTAGCA-GACATTGG-3Ј. The forward primer contained the EcoRI site to permit fusion of the IgSP directly to the second amino acid in the FGF-2 cDNA and the reverse primer contained the NotI site for cloning purposes. The reaction mixture contained 0.5 pm of both FGF-2 forward and reverse primers, 4% DMSO, 2.5 mm dNTPs, 5× PCR buffer and 0.5 l of Taq gold polymerase (Perkin Elmer). PCR was carried out using the reaction conditions: 1 min at 94°C, 2 min at 65°C, and 2 min at 72°C for 35 cycles. The PCR product was subcloned into the pCR2.1 vector to form pCR2.1-FGF-2. The FGF-2 cDNA was excised from the pCR2.1-FGF-2 vector by NotI and EcoRI digestion and inserted as a NotI-EcoRI fragment into the pPIIgSP-Neo-DHFR vector to create the pPI-IgSP/FGF-2-Neo-DHFR fusion construct. All constructs were verified by sequencing and restriction analysis.
Transfection and generation of a stable cell line Murine C 2 C 12 myoblasts derived from skeletal leg muscle of an adult C3H mouse were obtained from American Type Culture Collection (ATCC; CRL 1777, Rockville, MD, USA). Five separate cell lines were obtained by stably transfecting C 2 C 12 myoblasts with either pPI-Neo-DHFR (empty vector), pPI-VEGF 121 -Neo-DHFR, pPI-VEGF 165 -Neo-DHFR, pPI-FGF-2-Neo-DHFR or pPIIgSP/FGF-2-Neo-DHFR constructs using calcium phosphate precipitation (mammalian transfection kit; Stratagene, CA, USA). Stable transfectants were selected by a 2 week application of G418 (0.8 mg/ml) to the culture media consisting of Dulbecco's modified Eagle's medium (DMEM), 10% fetal bovine serum (FBS), 2 mm l-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin. Amplification of gene copy number was accomplished by adding methotrexate (Sigma, Buchs, Switzerland) in incremental doses starting at 1 m and progressing to 200 m over 6 weeks. Cells were maintained in 50 m of methotrexate following the selection period.
Cell encapsulation
Capsules measuring 1 or 2 cm in length were fabricated using microporous polyethersulfone (PES) hollow fibers (OD, 600 m; ID, 480 m; molecular weight cutoff, 280 kDa) (Akzo Nobel Faser, Wuppertal, Germany). Two centimeter capsules contained a reinforcing titanium coil in the inner lumen to enhance the mechanical properties of the membrane following transplantation. C 2 C 12 cells were harvested using a 0.125% trypsin-EDTA solution prepared in modified Puck's saline, and were diluted with DMEM in order to achieve a suspension of 1 × Measurement of VEGF and FGF-2 secretion C 2 C 12 -empty vector, C 2 C 12 -VEGF 121 , C 2 C 12 -VEGF 165 , C 2 -C 12 -FGF-2 and C 2 C 12 -IgSP/FGF-2 unencapsulated cell lines were assessed for their secretion levels of either VEGF or FGF-2 in vitro. VEGF cell lines were plated in a six-well plate at a density of 100 000 cells per well. The following day, cells were incubated in 2 ml of fresh medium (DMEM containing 10% FBS) for a 1 h release period. Cell lines secreting FGF-2 were also plated in a six-well plate, but at a higher density of 250 000 cells per well. The following day, cells were incubated in 1 ml of fresh medium (DMEM containing 10% FBS) for 1.5 h. Changes in the release protocol between VEGF and FGF-2 cell lines were made to adjust for differences in the levels of growth factor released. Secretion levels of either VEGF or FGF-2 by encapsulated cells were evaluated within 24 h before implantation. Conditioned media for VEGF and FGF-2 encapsulated cells were measured following either a 1 h or 45 min release period, respectively. VEGF and FGF-2 levels were measured using an enzymelinked immunosorbent assay (ELISA) for human VEGF or FGF-2 (Quantikine IVD, R&D Systems, Minneapolis, MN, USA). Secretion levels of VEGF and FGF-2 determined in this manner were normalized to g/10 6 cells per day and ng/10 6 cells per day, respectively.
In vitro angiogenesis assay
Bovine microvascular endothelial (BME) cells derived from the adrenal cortex 56 were provided by Drs MB Furie and SC Silverstein (Columbia University, NY, USA). BME cells were cultured in miminal essential medium, alphamodification (␣-MEM) (Gibco BRL Life Technologies), 15% donor calf serum (DCS) and antibiotics. Recombinant human FGF-2 was kindly provided by P Sarmientos (Farmitalia Carlo Erba, Milan, Italy). Recombinant human VEGF (165-amino acid homodimeric species) was purchased from PeproTech (Rocky Hill, NJ, USA). Threedimensional collagen gels were prepared in 18-mm tissue culture wells as described. 36 For cocultures, C 2 C 12 cell lines were seeded in suspension at 1 × 10 5 cells/ml in a 350 l collagen gel. This gel was subsequently overlaid with a second, 250 l cell-free layer of collagen. BME cells were then seeded on top of the second layer of collagen at 2 × 10 5 cells/ml in ␣-MEM/DMEM 1:1 plus 5% DCS ( Figure 2B) . A series of controls were performed in parallel, in which BME cells were seeded on to 500 l cellfree collagen gel casts into 18-mm tissue culture wells. Medium employed was as for cocultures ( Figure 2A ). After 2-3 days, when the BME cells had reached confluence, medium was changed and DCS reduced to 2%. Cocultures were not treated further. Control cultures containing only BME cells were treated either with rhFGF-2 (10 ng/ml) or with rhVEGF 165 (100 ng/ml). Medium and cytokines were renewed every 2-3 days. Cocultures were photographed after 5 and 7 days; cytokine-treated cultures were photographed after 2 and 4 days of treatment. Invasion was quantified from three randomly selected 1 × 1.4 mm fields per well, by measuring the total length of all cells which penetrated into the underlying gel either as single cells or in the form of cell cords. 38 Results are from at least three experiments, ie at least nine microscopic fields per condition (three measurements per experiment). Values are expressed as mean ± s.e.m. Data were analyzed using the unpaired t test. A significant value was taken as P Ͻ 0.5.
Ischemic skin flap model
All experiments were conducted with the approval of the Animal Experimentation Ethics Committee at the Geneva University Hospital. Female Wistar rats, weighing 250-300 g, were anesthetised by intraperitoneal injection of Gene Therapy sodium pentobarbital, 35 mg/kg. A caudally based 9 × 3 cm dorsal skin/panniculus carnosus flap was raised with the two constant sacral axial vessels systematically cut. The caudal border of the flap was marked 1 cm below the posterior iliac crests. Capsules secreting either VEGF or FGF-2 were positioned longitudinally on the subcutaneous tissue at the distal end of the skin flap. A single 8.0 nonresorbable suture was placed at the capsule midpoint. The skin flap was immediately resutured in place. Post-operatively, animals were fed ad libitum and housed in individual cages.
Method of evaluating flap survival
Each flap was examined on a daily basis following operation. The extent of necrosis was noted at each evaluation. On post-operative day 7, the margin of the flaps and the necrotic edges were traced on an acetate sheet. The regions of necrosis were defined as zones of full thickness flap necrosis as well as unhealed areas (covered with scab or not yet epithelialized). The total flap surface area and the regions of necrosis were measured using a polar planimeter computerized image analysis system, which permits two-dimensional area measurements. A cursor traces the outline of the areas of interest and the program displays the corresponding area data. Each measurement was performed three times by a single operator and the average values constituted the final result. Standard deviations were calculated to assess the variability of the method. Quantitation of flap necrosis was expressed as a percentage of the total flap surface area (necrotic area/total area). Data obtained from different treatment groups were analyzed by ANOVA using the Kruskal-Wallis test and the Dunn's multiple comparison test. Animals were killed at post-operative day 7 by intracardiac pentobarbital overdose, 200 mg per kilogram. Immediately following death, microangiography was performed and sections of the flaps were removed for histology.
Microangiography
Flaps and surrounding vessels connected to the recipient bed were evaluated by barium-sulfate microangiography at 1 week after operation. Post-mortem angiography was performed by catheterization of the left carotid artery (22G/25mm), into which 150 ml of a mixture containing 13.5 g of barium-sulfate, 4 ml of green india ink (Pelikan) and 123 g of gelatin powder was injected. The total dorsal skin of the rat, including the flap was harvested 24 h later and X-rays were performed using a mammograph (General Electric, Fairfield, CT, USA) with exposure conditions of 10 to 16 mA and 24 to 27 kV. X-rays were then scanned (HP Scanjet IICX/T, Palo Alto, CA, USA) and selected for analysis based on opacification of the normally perfused skin adjacent to the flap. A Leica Quantimet 500 computer program (Nussloch, Germany) was used to quantify the overall surface of the opacified vessels within the flap in a frame of 445 × 366 pixels. This frame was placed in the distal area and in the proximal area to measure the extent of vascularization in each of these zones. To correct for variations in the filling of the vascular tree, for each flap, vascularization of the distal area was expressed in relation to the proximal area (distal opacity/proximal opacity) to allow for comparison between different flaps.
Histological analysis of skin flaps and explanted capsules Skin flaps were harvested with the underlying tissues containing capsules on day 7, and fixed in Formalin of Bouin's fixative. Tissues were embedded in paraffin, cut at 5 m thickness and stained with hematoxylin and eosin. For lectin immunohistochemistry, 5 m sections were deparaffinized, washed with water, digested in 0.1% trypsin in 0.1% CaCl 2 , pH 7.8 for 10 min at 37°C and quenched in a mixture of 3% H 2 O 2 in methanol for 10 min at room temperature. Samples were incubated for 2 h at room temperature with a 1:50 dilution of GSA I-B4 lectin (Sigma L5391; St Louis, MO, USA) coupled to horseradish peroxidase in 1% BSA in PBS. Labeled cells were visualized with 3,3ЈЈ-diaminobenzidine (Sigma). At the experimental endpoint, capsules were carefully explanted, fixed in Lang's fixative for 3 h and dehydrated using alcohol in preparation for glycol-methacrylate embedding (Leica Instruments). After removing the titanium reinforcement, the capsules were cut at 5 m thickness and stained with hematoxylin and eosin.
